J&J’s new pivotal study in coronary artery disease, dubbed FORWARD CAD, will test a cardiac-focused version of the Javelin as ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

A shocking new study reveals that a condition that can lead to limb amputation is far more prevalent and deadly than ...

According to national statistics, nearly a quarter of U.S. adults ages 75 and older have heart disease, an umbrella term for a cluster of heart conditions, including coronary artery disease and heart ...

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), ...

A vascular surgeon at SSM Health St. Mary's Hospital will hold two free discussions about peripheral arterial disease, which ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Anyone who has a diagnosis of peripheral artery disease (PAD) now has access to a “proven, effective treatment” at Pawnee ...

Peripheral artery disease (PAD) can lead to gangrene or amputation yet is often overlooked - experts have warned that just ...

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT. About LeMaitre ...

For decades, the clinical approach to coronary artery disease has been centred on the acute effects of coronary occlusion and ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...